US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With

Authors: Asma Dilawari, James Buturla, Christy Osgood, Xin Gao, Wei Chen, Tiffany K. Ricks, Timothy Schaefer, Sreedevi Avasarala, Francisca Reyes Turcu, Anand Pathak, Shyam Kalavar, Vishal Bhatnagar, Justin Collazo, Nam Atiqur Rahman, Bronwyn Mixter, Shenghui Tang, Richard Pazdur, Paul Kluetz, Laleh Amiri-Kordestani

Published: 2024-08-19

DOI: 10.1200/jco.24.00427

Source: Full article

---

Abstract

PURPOSE